Form 4: Kura Oncology CLO Granted 50,000 RSUs, 100,000 Options

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, was granted 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock.

Summary

• Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, Inc., acquired 50,000 shares of common stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• The RSUs were acquired at a price of $0 per share and will vest in four equal annual installments on January 26, 2027, January 26, 2028, January 26, 2029, and January 26, 2030.
• Following this transaction, Teresa Brophy Bair beneficially owns 238,139 shares of common stock.
• Additionally, Teresa Brophy Bair acquired options to purchase 100,000 shares of common stock on January 2, 2026.
• These options have an exercise price of $10.335 per share and were acquired at a price of $0.
• The options will vest in 48 equal monthly installments commencing on the grant date and have an expiration date of January 1, 2036.
• Following this transaction, Teresa Brophy Bair beneficially owns 100,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects standard executive compensation practices designed to incentivize and retain key management, aligning their interests with long-term company performance. This is a routine, non-eventful filing for a public company.

Positives

• The grant of equity awards (RSUs and stock options) to the Chief Legal Officer serves as a strong incentive for executive retention and aligns management's interests with those of shareholders.
• The vesting schedules for both RSUs and options encourage long-term commitment and performance from a key executive.

Future Outlook

The future outlook indicates a long-term incentive structure for the Chief Legal Officer, with RSUs vesting over four years and options vesting monthly over 48 months, encouraging sustained performance and alignment with company growth through 2030 and 2036, respectively.

Industry Context

The grant of equity awards such as Restricted Stock Units and stock options is a standard practice in the biotechnology and pharmaceutical industry for executive compensation. This approach is widely used to attract, retain, and motivate key personnel by aligning their financial interests with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• Equity grants to executives, including RSUs and stock options with multi-year vesting schedules, are a common compensation strategy across the biotech sector, comparable to practices at companies like Moderna, Biogen, or Amgen, which frequently use such incentives to retain top talent.
• The specific number of shares and options granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, reflecting the executive's role and contribution, though specific peer data is not provided in this filing.

Related Party Transactions

• The grant of 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock to Teresa Brophy Bair, the Chief Legal Officer, constitutes a related party transaction as it involves compensation from the company to an executive.

Stakeholder Impact

• Shareholders: The grants incentivize the Chief Legal Officer, potentially leading to better long-term performance, but also represent potential future dilution upon vesting and exercise of the awards.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.
• Management: The grants provide significant long-term financial incentives, aligning the Chief Legal Officer's personal wealth with the company's stock performance.

Next Steps

• Continued vesting of 50,000 Restricted Stock Units in four equal annual installments through January 26, 2030.
• Continued vesting of options to purchase 100,000 shares in 48 equal monthly installments commencing January 2, 2026.
• Potential exercise of vested stock options by Teresa Brophy Bair prior to the January 1, 2036 expiration date.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Grant